Who
Sarah Joanne Williams
Principal Accounting Officer
Company insider
Files Form 4 as: Principal Accounting Officer, AN2 Therapeutics.
In numbers
- Trades disclosed
- 8
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $6,049
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Feb 2026
- Last trade
- 1 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 4 Sep 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,504272 at $5.53 | filing |
| 1 Sep 2026filed 4 Sep 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,504272 at $5.53 | filing |
| 29 May 2026filed 2 Jun 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,174265 at $4.43 | filing |
| 29 May 2026filed 2 Jun 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,174265 at $4.43 | filing |
| 3 Mar 2026filed 5 Mar 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $347327 at $1.06 | filing |
| 3 Mar 2026filed 5 Mar 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $347327 at $1.06 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —48,375 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —48,375 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.